As we prepare to launch our fourth enzyme replacement therapy, our passion for solving serious medical problems and providing new hope to patients is stronger than ever.

Genzyme has pioneered the treatment of lysosomal storage disorders (LSDs), genetic diseases caused by enzyme deficiencies. At the close of 2005, we had three LSD therapies on the market. Today, we are anticipating approval of Myozyme for Pompe disease in Europe and the United States and plan to launch this new LSD therapy in the second quarter of the year. LSDs share common traits, but each one has a different set of challenges. Each of our successive LSD products has benefited from our growing experience, and we continue to invest in advances in patient care and expanded access for all of these products.

Growth and investment in LSD therapies
Sales of Fabrazyme, our therapy for Fabry disease, grew 45 percent during 2005. More than 1,700 patients in over 40 countries are treated with this therapy. At the end of its first full year on the market in Japan, there were more than 250 patients on Fabrazyme. In Europe, the product's label has been expanded based on the findings from our post-marketing study, and we anticipate a similar label change in the United States. We are using information from patient registries to continue to build our knowledge base for more effective use of Fabrazyme. While this disease is most prevalent in young men, we are also investigating it in women and children.

Aldurazyme is the treatment we developed jointly with BioMarin Pharmaceutical Inc. for MPS I. Now available in more than 30 countries, Aldurazyme is making a major difference for more than 400 children and adults who have this disease. We are continuing to support earlier diagnosis and treatment, and we are conducting a post-marketing study of Aldurazyme in MPS I patients under age 5. As part of our effort to improve the lives of MPS I patients, we are also investigating the role of this therapy in conjunction with bone marrow transplantation.

Cerezyme remains the global standard of care for Gaucher disease, but we nevertheless continue to innovate on behalf of Gaucher patients. We are investing in product enhancements that offer greater convenience and other patient benefits. Even after it has been on the market for 15 years, we continue to use our profits to fund scientific and clinical research to improve Cerezyme and to ensure capacity by investing in manufacturing scale and redundancy. Additionally, we are pursuing phase 2 clinical studies of a small molecule therapy for Gaucher disease and preclinical research of an LSD gene therapy.

Commitment to access
Genzyme's foundation in the LSDs is also the foundation of our patient focus. To reach these patients with life-sustaining therapies, not only have we made deep investments in preclinical, clinical, and post-marketing research. We have supported global patient registries and made certain that our research studies have worldwide applicability. We have built a vertically integrated company to bring therapies to patients as quickly and reliably as possible. We have made a commitment to global access, which has led us to create humanitarian programs and to work closely with governments and insurers to recognize both the value and financial realities of therapies that cannot achieve economies of scale.